Product Description
A humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1; SELPLG; CD162), with potential immunosuppressive activity. Upon administration, neihulizumab specifically targets and binds to CD162 expressed on activated T-lymphocytes. This induces apoptosis of activated T-cells and reduces T-cell-mediated immune responses. This may halt disease progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/neihulizumab)
Mechanisms of Action: PSGL-1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: Fast Track - Graft vs Host Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbGenomics International
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psoriasis|Graft vs Host Disease|Arthritis, Psoriatic|Colitis, Ulcerative
Phase 1: Psoriasis|Healthy Volunteers|Graft vs Host Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04144036 |
PRO36517 | P1 |
Completed |
Graft vs Host Disease |
2023-04-20 |
2024-10-02 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03327857 |
TR-aGVHD | P1 |
Completed |
Graft vs Host Disease |
2022-09-30 |
50% |
2023-01-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT02436460 |
BMT 285 | P1 |
Terminated |
Graft vs Host Disease |
2016-03-01 |
2019-03-20 |
Treatments |
|
NCT01378364 |
NCT01378364 | P1 |
Completed |
Healthy Volunteers |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT00848055 |
NCT00848055 | P1 |
Completed |
Psoriasis |
2010-10-01 |
2019-03-18 |
Treatments |
|
NCT03298022 |
TNF | P2 |
Terminated |
Colitis, Ulcerative |
2020-04-06 |
25% |
2023-07-07 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT02694770 |
NCT02694770 | P2 |
Withdrawn |
Graft vs Host Disease |
2017-09-01 |
2019-03-20 |
Treatments |
|
NCT02267642 |
NCT02267642 | P2 |
Completed |
Arthritis, Psoriatic |
2015-10-01 |
2019-03-20 |
Treatments |
|
NCT02223039 |
NCT02223039 | P2 |
Completed |
Psoriasis |
2014-12-01 |
2019-03-20 |
Treatments |
|
NCT01855880 |
AbGn-168H | P2 |
Completed |
Psoriasis |
2014-02-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/01/2023 |
News Article |
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis |
|
06/15/2023 |
News Article |
AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting |
|
05/31/2023 |
News Article |
AltruBio to Present at the 2023 BIO International Convention |
|
05/08/2023 |
News Article |
AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023 |